Want to see HK:2157 full AI Analyst Report?
2157 Stock Chart & Stats
HK$4.48
HK$0.18(3.79%)
At close: 4:00 PM EDT
HK$4.48
HK$0.18(3.79%)
Day’s Range― - ―
52-Week RangeHK$3.55 - HK$8.11
Previous CloseN/A
Volume10.92M
Average Volume (3M)11.17M
Market Cap
HK$7.59B
Enterprise ValueHK$7.44K
Total Cash (Recent Filing)HK$788.84M
Total Debt (Recent Filing)HK$1.18B
Price to Earnings (P/E)25.3
Beta0.98
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,804,439,800
10 Day Avg. Volume9,333,146
30 Day Avg. Volume11,168,799
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)5.65
Price to Sales (P/S)8.60
P/FCF Ratio-94.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.66Price Target Upside26.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.04
Revenue Forecast (FY)HK$1.07B
Bulls Say, Bears Say
Bulls Say
2025 Revenue And Profit InflectionThe sharp 2025 revenue increase and transition from deep losses to a sizable profit show meaningful operating progress. If sustained, this larger commercial base can support reinvestment in oncology development, strengthen operating leverage, and improve the company’s ability to fund growth over the next several quarters.
Very High Gross MarginsGross margins above 80% indicate attractive unit economics for the reported business and provide substantial room to absorb research, commercialization, and operating costs. Maintaining this margin profile could support durable profitability as product revenue expands, although execution remains important during the company’s growth phase.
Broad Oncology Innovation PlatformA diversified oncology pipeline spanning ADCs, monoclonal antibodies, and small molecules gives the company multiple development avenues rather than relying on one therapeutic format. Progress across these programs could create additional commercialization and licensing opportunities over the medium term.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow despite reported profitability show that earnings are not yet converting into cash. Continued cash burn can increase reliance on external funding, constrain investment choices, and leave less financial flexibility to advance clinical programs or withstand weaker operating periods.
Volatile Profitability HistoryThe rapid shift from substantial losses to profit makes the 2025 earnings improvement difficult to regard as fully established. Historical volatility raises execution risk around commercialization and cost control, and a reversal could weaken confidence in the durability of future earnings and internal funding capacity.
Meaningful And Rising Debt LoadAlthough debt-to-equity improved as equity expanded, the absolute debt balance still rose to about 1.06B. This obligation can reduce financial flexibility and increase pressure on cash resources if earnings or cash conversion weaken, particularly while the company continues investing in biotech development.
Lepu Biopharma Co. Ltd. Class H News
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$3.55 and its highest was HK$8.11 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$7.59B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 187 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Aug 19, 2026. The company reported HK$0.023 earnings per share for the quarter.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Undervalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.023 in its last earnings report. Following the earnings report the stock price went down -3.656%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$5.66 (26.34% Upside)
HK$5.66 (26.34% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
2157 Stock 12 Month Forecast
Average Price Target
HK$5.66
▲(26.34% Upside)
Technical Analysis
Genscript Biotech
―
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―